OPINION: View from the summit
01 November, 2005 by Stuart RobertsSouthern Cross Equities biotech analyst Stuart Roberts was behind the recent DNA, Devices and Dealers conference in Sydney. Here, he explains his passion for hanging out with biotech's true believers.
A super way to invest in biotech
31 October, 2005 by Ruth BeranWhat are the odds that Australians' precious nest eggs be used to invest in something as risky as biotech? Well guess what -- it's already happening, and governments face pressure to free up more superannuation funds, writes Ruth Beran.
Riding the biotech rollercoaster
26 October, 2005 by Fiona RotherhamExpat Kiwi Simon Moroney knows all too well the vagaries of the share market through his listed German biotech company, MorphoSys, writes Fiona Rotherham.
Biotech made simpler: new code aims to help CEOs and investors
25 October, 2005 by Ruth BeranIt's hardly surprising that one of the Australian biotechnology industry's biggest bugbears is a communication gap between companies and their investors.
Solbec chooses initial tumour targets
24 October, 2005 by Helen SchullerSolbec Pharmaceuticals (ASX:SBP) has selected malignant melanoma and metastatic renal cell carcinoma (mRCC) as the first two tumour types for multiple target activity phase II trials of its lead compound Coramsine in the treatment of advanced tumours.
Tenders close for new CRC host
24 October, 2005 by Susan WilliamsonThree Victorian institutes, the MacFarlane Burnet Institute for Medical Research and Public Health, the University of Melbourne and the Victorian Infectious Diseases Reference Laboratory, have applied to host the WHO Collaborative Centre for Reference and Research on Influenza, which is currently based at the CSL site in Parkville, Melbourne.
Epitan files patent, Norwood Abbey granted patent
24 October, 2005 by Ruth BeranMelbourne-based Epitan (ASX:APT, ADR:EPTNY, XETRA:UR9) has filed for a full international patent to protect the commercial use of the topical formulation of its melanin producing drug EPT1647 (formerly Melanotan).
In brief: Regenera, Compumedics, SciGen
21 October, 2005 by Ruth BeranRegenera (ASX:RGA) has appointed Hon Dr Michael Woodridge as non-executive chairman effective immediately, subject to shareholder approval.
Agenix raises AUD$10.3m
21 October, 2005 by Ruth BeranBrisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) has raised a total of AUD$10.3 million through a non-renounceable 1:4 entitlements offer.
LCT files for pre-IND meeting with FDA
20 October, 2005 by Helen SchullerLiving Cell Technologies (ASX:LCT) has filed a request for a pre-IND meeting with the US FDA to seek guidance and feedback on the development program for its NeurotrophinCell (NtCell) product for the treatment of Huntington's disease.
In brief: MediVac, C3, Premier Bionics
20 October, 2005 by Ruth BeranBob Atwill will join MediVac (ASX:MDV) as a consultant to assist in the commercialisation of the company's MetaMizer series II. Atwill was formerly sales and marketing director of London Stock Exchange listed orthopaedic company Corin Group.
Resolution in sight for Ventracor and HeartWare legal dispute
19 October, 2005 by Helen SchullerVentracor (ASX:VCR) and HeartWare (ASX:HTW) have commenced negotiations to settle an on-going patent dispute between the two artificial heart firms.
Premier Bionics plans AIM listing
19 October, 2005 by Ruth BeranPremier Bionics (ASX:PBI) is seeking to list on London's Alternative Investment Market (AIM).
Epitan raises AUD$6.9 m, plans AIM listing
19 October, 2005 by Ruth BeranMelbourne-based Epitan (ASX:EPT, ADR:EPTNY, XETRA:UR9) has raised AUD$6.9 million before costs via a private placement to institutional and private investors and will once again seek to list on London's AIM stock market.
Acrux's US partner completes enrolment for phase III trial
18 October, 2005 by Ruth BeranMelbourne-based Acrux's (ASX:ACR) US partner Vivus (NASDAQ:VVUS) has completed enrolment for its phase III clinical study of Acrux's estradiol transdermal spray product Evamist for the treatment of menopausal symptoms.
